Wednesday, July 17, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for an engaging conversation on strategies to optimize patient outcomes and manage costs in Wet Age-Related Macular Degeneration.

Neovascular, or wet, age-related macular degeneration (wet AMD) is a significant cause of central visual impairment, contributing to about half of all cases of blindness in Americans aged 50 years and older. The estimated number of individuals affected by wet AMD in the United States is projected to double to 5.4 million between 2010 and 2050. Although there is currently no cure for wet AMD, there are treatment options that slow disease progression.

In this webinar, key panelists will share insights curated from AMCP's Market Insights program on the patient burden of wet AMD and how payers can best manage it by considering factors such as timeliness of treatment, treatment durability, and cost-effective treatment strategies.

Learning Objectives

• Outline the clinical, mental, and economic burdens associated with wet AMD and its treatments.
• Provide insights on the prevalence and severity of wet AMD in the United States.
• Explore treatment modalities for wet AMD, gaining insights into the value of therapeutic strategies and advancements in managing wet AMD.
• Identify benefit design strategies that facilitate appropriate and timely treatment of wet AMD.
• Identify opportunities for payer and provider collaboration to improve the management of wet AMD.